← All trials
NCT05253105
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 15, 2022
- Primary completion
- Sep 30, 2026
- Completion date
- Jan 31, 2027
- First posted
- Feb 23, 2022
- Last posted
- May 31, 2022
- Enrollment
- 0
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shanghai Junshi Bioscience Co.,Ltd.Lead sponsor
- Shanghai Junshi Bioscience Co.,Ltd.Collaborator
- Shanghai Junshi Bioscience Co.,Ltd.Study director
- CTI Clinical Trial and Consulting ServicesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.